Arcutis Biotherapeutics (ARQT)
22.00
+0.05 (0.23%)
Upcoming Events
Latest Headlines
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
June 3, 2026 8:00 AM - StreetInsider
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026 4:00 PM - Globe NewsWire
Form 4 Arcutis Biotherapeutics, For: May 11 Filed by: Vairavan Latha
May 13, 2026 7:43 PM - SEC Filing
Form 4 Arcutis Biotherapeutics, For: May 11 Filed by: Burnett Patrick
May 13, 2026 7:42 PM - SEC Filing
Form SCHEDULE 13G Arcutis Biotherapeutics, Filed by: STATE STREET CORP
May 12, 2026 9:55 AM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
May 11, 2026 4:46 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Vairavan Latha
May 11, 2026 4:36 PM - SEC Filing
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026 4:00 PM - Globe NewsWire
Form SCHEDULE 13G/A Arcutis Biotherapeutics, Filed by: PRUDENTIAL FINANCIAL INC
May 8, 2026 11:09 AM - SEC Filing
Arcutis Biotherapeutics Inc. (ARQT) PT Lowered to $34 at Morgan Stanley
May 7, 2026 9:00 AM - StreetInsider
Form 4 Arcutis Biotherapeutics, For: May 04 Filed by: Matsuda Masaru
May 6, 2026 7:40 PM - SEC Filing
Form 4 Arcutis Biotherapeutics, For: May 04 Filed by: Burnett Patrick
May 6, 2026 6:15 PM - SEC Filing
Form 4 Arcutis Biotherapeutics, For: May 04 Filed by: Vairavan Latha
May 6, 2026 6:13 PM - SEC Filing
Form 4 Arcutis Biotherapeutics, For: May 04 Filed by: Watanabe Todd
May 6, 2026 6:06 PM - SEC Filing
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q1 EPS by 4c
May 6, 2026 5:07 PM - StreetInsider
Form SCHEDULE 13G/A Arcutis Biotherapeutics, Filed by: JENNISON ASSOCIATES LLC
May 6, 2026 4:13 PM - SEC Filing
Form 10-Q Arcutis Biotherapeutics, For: Mar 31
May 6, 2026 4:08 PM - SEC Filing
Form 8-K Arcutis Biotherapeutics, For: May 06
May 6, 2026 4:04 PM - SEC Filing
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026 4:00 PM - StreetInsider
Form 4 Arcutis Biotherapeutics, For: May 01 Filed by: Welgus Howard G.
May 5, 2026 8:22 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrick
May 4, 2026 5:19 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Vairavan Latha
May 4, 2026 5:19 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd
May 4, 2026 5:18 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
May 4, 2026 5:05 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
May 1, 2026 4:05 PM - SEC Filing
Arcutis submits FDA application to expand ZORYVE cream for infants
April 27, 2026 8:01 AM - StreetInsider
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
April 27, 2026 8:00 AM - Globe NewsWire
Arcutis' ZORYVE cream gets strong AAD recommendation for pediatric atopic dermatitis
April 22, 2026 8:04 AM - StreetInsider
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
April 22, 2026 8:00 AM - StreetInsider
Form S-8 Arcutis Biotherapeutics,
April 21, 2026 4:50 PM - SEC Filing
Form ARS Arcutis Biotherapeutics, For: Apr 21
April 21, 2026 4:42 PM - SEC Filing
Form DEFA14A Arcutis Biotherapeutics,
April 21, 2026 4:40 PM - SEC Filing
Form DEF 14A Arcutis Biotherapeutics, For: Apr 21
April 21, 2026 4:38 PM - SEC Filing
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
April 15, 2026 4:00 PM - Globe NewsWire
The Credibility Filter Wall Street Uses to Sort Biotech Winners
April 8, 2026 9:15 AM - StreetInsider
Palvella Therapeutics names Kent Taylor sales chief
April 7, 2026 12:26 PM - StreetInsider
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 7, 2026 12:26 PM - Globe NewsWire
Form 4 Arcutis Biotherapeutics, For: Apr 01 Filed by: Welgus Howard G.
April 3, 2026 5:46 PM - SEC Filing
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
April 1, 2026 4:03 PM - SEC Filing
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
March 31, 2026 4:00 PM - Globe NewsWire
Arcutis presents infant atopic dermatitis trial data at dermatology meeting
March 28, 2026 11:00 AM - StreetInsider
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
March 28, 2026 11:00 AM - StreetInsider
Form SCHEDULE 13G/A Arcutis Biotherapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 11:13 AM - SEC Filing
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
March 18, 2026 8:00 AM - StreetInsider
Arcutis publishes long-term ZORYVE safety data for pediatric atopic dermatitis
March 10, 2026 9:00 AM - StreetInsider
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pedi
March 10, 2026 9:00 AM - StreetInsider
Full Article List
